Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3012% below fair value
$20.94−1.89 (-8.28%)
Close on Nov 16, 2026Market cap $2.16BP/E –Yield –
Beam Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Beam Therapeutics's enterprise value was $1.57B on Nov 11, 2026, against $1.47B a year earlier. Over the last 5 years it ranged from $391.82M to $4.46B, with a median of $1.35B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.57B | -8.4% |
| 2025 | Dec 31, 2025 | $1.71B | +52.4% |
| 2024 | Dec 31, 2024 | $1.12B | -3.4% |
| 2023 | Dec 29, 2023 | $1.16B | -29.9% |
| 2022 | Dec 30, 2022 | $1.66B | -62.9% |
| 2021 | Dec 31, 2021 | $4.46B | +14.0% |
| 2020 | Dec 31, 2020 | $3.92B | – |
See a number that looks wrong?